3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
3
Unknown
2
Completed
2
Enrolling by invitation
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
1663
Neoplasms, Plasma Cell
415
Lymphoma, Non-Hodgkin
311
Lymphoma
283
Hodgkin Disease
281
Leukemia, Lymphocytic, Chronic, B-Cell
274
Precursor Cell Lymphoblastic Leukemia-Lymphoma
246
Leukemia, Myeloid, Acute
223
Leukemia
220
Lymphoma, Mantle-Cell
196
Lymphoma, Large B-Cell, Diffuse
196
Lymphoma, Follicular
196
Myelodysplastic Syndromes
194
Recurrence
185
Lymphoma, B-Cell, Marginal Zone
178
Burkitt Lymphoma
172
Lymphoma, Large-Cell, Immunoblastic
161
Myeloproliferative Disorders
146
Leukemia, Myeloid, Chronic-Phase
134
Leukemia, Myeloid, Accelerated Phase
122
Primary Myelofibrosis
121
Immunoglobulin Light-chain Amyloidosis
120
Waldenstrom Macroglobulinemia
119
Lymphoma, T-Cell, Cutaneous
119
Blast Crisis
114
Leukemia, Myelomonocytic, Chronic
105
Sezary Syndrome
100
Mycosis Fungoides
100
Neoplasms
97
Leukemia, Hairy Cell
95
Interventions
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Amyloid Neuropathies, Familial
×
Plasma cell
×
Clear all
NCT05184088
2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3
Completed
244 enrolled
NCT03431896
2026-03-12
MED-hATTR
The Cleveland Clinic
Completed
37 enrolled